Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.54 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2230140 | 0.92 | NPC1 (0.79) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL124395 | 0.92 | NPC1 (0.79) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27945424 | 0.90 | NPC1 (0.76) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| Bicarbonate SCHEMBL11025569 | 0.90 | NPC1 (0.76) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23573216 | 0.87 | NPC1 (0.71) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2316588 | 0.85 | NPC1 (0.68) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL161227 | 0.85 | NPC1 (0.72) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17627163 | 0.85 | NPC1 (0.68) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12425958 | 0.84 | NPC1 (0.67) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6931601 | 0.84 | NPC1 (0.67) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116253719-B | Estrogen and androgen receptor dual degradation agent and application thereof | 苏州国匡医药科技有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-116253719-A | Estrogen and androgen receptor dual degradation agent and application thereof | 苏州国匡医药科技有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-9611279-B2 | Zinc complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-04-04 | — | — | US | disclosed |
| US-9611279-B2 | Zinc complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-04-04 | — | — | US | disclosed |
| US-20160002268-A1 | ZINC COMPLEX | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20160002268-A1 | ZINC COMPLEX | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-01-07 | — | — | US | disclosed |
| EP-2935260-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | Bayer Pharma Aktiengesellschaft (DE) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014095774-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-06-26 | — | — | WO | disclosed |
| EP-2593426-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| CN-1285636-C | Process for producing oxyalkylene derivative | MITSUI CHEMICALS INC (JP) | 2006-11-22 | — | — | CN | disclosed |
| CN-1781985-A | Epoxy resin composition, cured article obtained from the epoxy resin, and semiconductor device obtained thereof | MITSUI CHEMICALS INC (JP) | 2006-06-07 | — | — | CN | disclosed |
| CN-1200915-C | Process for preparing organic compound | MITSUI CHEMICALS INC (JP) | 2005-05-11 | — | — | CN | disclosed |
| CN-1592764-A | Method for producing organic compound, epoxy resin composition, cured product of the epoxy resin, and semiconductor device formed using the epoxy resin | MITSUI CHEMICALS INC (JP) | 2005-03-09 | — | — | CN | disclosed |
| US-20040260039-A1 | Process for producing organic compound epoxy resin composition, cured article obtained from the epoxy resin, and semiconductor device obtained with epoxy resin | MITSUI CHEMICALS, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-0950649-B1 | A process for preparing oxyalkylene derivatives in the presence of phosphine oxides | MITSUI CHEMICALS INC (JP) | 2003-03-26 | — | — | EP | disclosed |
| US-6130346-A | ESTERIFICATION, CARBONATION, SULFONATION, ETHERIFICATION | MITSUI CHEMICALS, INC. (JP) | 2000-10-10 | — | — | US | disclosed |
| CN-1235141-A | Process for preparing organic compound | MITSUI CHEMICALS INC (JP) | 1999-11-17 | — | — | CN | disclosed |
| EP-0950649-A1 | A process for preparing oxyalkylene derivatives in the presence of phosphine oxides | Mitsui Chemicals, Inc. (JP) | 1999-10-20 | — | — | EP | disclosed |
| US-3960945-A | 4-[-(Alkoxy or polyhaloalkoxy)-benzamido]cyclohexanones | STERLING DRUG INC. (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002268-A1 | ZINC COMPLEX | SLC39A11, SLC39A3, SOD1 | NPC1 845/4885RAB9A 2598/4885MEN1 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.